Track topics on Twitter Track topics that are important to you
Metabotropic Glutamate Receptor 3 GPRC1C or MGLUR3 or GRM3 Pipeline Review, H1 2018
According to the recently published report 'Metabotropic Glutamate Receptor 3 Pipeline Review, H1 2018'; Metabotropic Glutamate Receptor 3 GPRC1C or MGLUR3 or GRM3 pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes.
Metabotropic Glutamate Receptor 3 GPRC1C or MGLUR3 or GRM3 Metabotropic glutamate receptor 3 is a G proteincoupled receptor encoded by the GRM3 gene. Lglutamate is the major excitatory neurotransmitter in the central nervous system and activates both ionotropic and metabotropic glutamate receptors. Glutamatergic neurotransmission is involved in most aspects of normal brain function and can be perturbed in many neuropathologic conditions. mGluR3 is expressed by glia and neurons in many brain regions and has a predominantly presynaptic distribution, consistent with its role as an inhibitory autoreceptor and heteroceptor. mGluR3 are coupled to Gi/o which inhibits adenylyl cyclase, decreasing the formation of cAMP.
The report 'Metabotropic Glutamate Receptor 3 Pipeline Review, H1 2018' outlays comprehensive information on the Metabotropic Glutamate Receptor 3 GPRC1C or MGLUR3 or GRM3 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Metabotropic Glutamate Receptor 3 GPRC1C or MGLUR3 or GRM3 targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 3 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Genetic Disorders and Oncology which include indications Depression, Anxiety Disorders, Attention Deficit Hyperactivity Disorder ADHD, Cognitive Impairment, DiGeorge Syndrome, Generalized Anxiety Disorder GAD, Glioma, Neurodegenerative Diseases, Parkinson's Disease, Pervasive Developmental Disorder PDD, Schizophrenia, Smoking Addiction and Treatment Resistant Depression.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 3 GPRC1C or MGLUR3 or GRM3
The report reviews Metabotropic Glutamate Receptor 3 GPRC1C or MGLUR3 or GRM3 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Metabotropic Glutamate Receptor 3 GPRC1C or MGLUR3 or GRM3 targeted therapeutics and enlists all their major and minor projects
The report assesses Metabotropic Glutamate Receptor 3 GPRC1C or MGLUR3 or GRM3 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Metabotropic Glutamate Receptor 3 GPRC1C or MGLUR3 or GRM3 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 3 GPRC1C or MGLUR3 or GRM3
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 3 GPRC1C or MGLUR3 or GRM3 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeNEXT ARTICLE
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...